Generated by All in One SEO v4.9.3, this is an llms.txt file, used by LLMs to index the site.

# Inventprise

Better Vaccines for a Better World

## Sitemaps

- [XML Sitemap](https://inventprise.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Inventprise Announces Positive Interim Results from the Phase 1/2 clinical study for Hexavalent Group B Streptococcal Vaccine Candidate (IVT GBS-06)](https://inventprise.com/2026/02/23/inventprise-announces-positive-interim-phase-1-2-results-for-hexavalent-maternal-group-b-strep-vaccine-candidate-ivt-gbs-06-presented-at-issad-2026/) - PRESS RELEASE Inventprise Announces Positive Interim Results from the Phase 1/2 clinical study for Hexavalent Group B Streptococcal Vaccine Candidate (IVT GBS-06) REDMOND, Wash., Feb 23, 2026 — Today at the ISSAD meeting in Nairobi, Kenya, Prof. Shabir Madhi from the Wits Vaccines & Infectious Diseases Analytics (VIDA) Research Unit, Johannesburg, South Africa, will present
- [<em>Vaccine Journal, Volume 54:</em> SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants](https://inventprise.com/wp-content/uploads/2025/03/INVENTPRISE_Carroll-M-et-al_-Vaccine-54-126988-2025_-SARS-CoV-2-conjugate-vaccine-elicits-robust-immune-responses.pdf#new_tab)
- [Inventprise Announces Breakthrough in COVID-19 Conjugate Vaccine Study Published in Vaccine Journal](https://inventprise.com/2025/06/24/inventprise-announces-breakthrough-in-covid-19-conjugate-vaccine-study-published-in-vaccine-journal/) - PRESS RELEASE Inventprise Announces Breakthrough in COVID-19 Conjugate Vaccine Study Published in Vaccine Journal REDMOND, Wash., June 24, 2025 — Inventprise, a clinical stage vaccine invention company, today announced the publication of a landmark preclinical study in Vaccine Journal (Vol. 54, April 30, 2025, Article 126988) showcasing the potential of its novel bivalent SARS-CoV-2 conjugate vaccine
- [Inventprise Selects Quantoom Biosciences’ Ntensify® Production Technology to Advance mRNA Vaccine Development](https://inventprise.com/2025/05/15/inventprise-selects-quantoom-biosciences-ntensify-production-technology/) - PRESS RELEASE Inventprise Selects Quantoom Biosciences’ Ntensify® Production Technology to Advance mRNA Vaccine Development REDMOND, Wash., & NIVELLES, Belgium – May 15, 2025 — Inventprise Inc., a clinical-stage vaccine invention company, announced today its selection of Quantoom Biosciences’ Ntensify midi system as the core technology to support its mRNA vaccine platform. mRNA technology is crucial
- [Path.com: A Deadly Disease for Infants Has No Vaccine—We’re Changing That](https://www.path.org/our-impact/articles/a-deadly-disease-for-infants-has-no-vaccinewere-changing-that/#new_tab) - INVENTPRISE IN THE NEWS Inventprise President & CEO Yves Leurquin Attends 2nd Global Forum on Childhood Pneumonia Yves Leurquin shared the vision and mission of Inventprise’s efforts in developing a high valency pneumococcal conjugate vaccine to provide broader coverage during the 2nd Global Forum on Childhood Pneumonia on April 27, 2023 in Madrid, Spain. Watch
- [Life Science Washington Welcomes New Board Members as the State’s Life Sciences Industry Strengthens Its Position as a Top 10 US Cluster](https://inventprise.com/2025/01/31/life-science-washington-welcomes-board-members/) - PRESS RELEASE Life Science Washington Welcomes New Board Members as the State’s Life Sciences Industry Strengthens Its Position as a Top 10 US Cluster Nine new executives represent some of the largest companies driving innovation in Washington state SEATTLE—Life Science Washington, the state’s life sciences industry association, today announced the expansion of its board of
- [Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate](https://inventprise.com/2024/01/02/inventprise-completes-vaccination-of-participants-in-a-phase-2-dose-ranging-study-of-its-25-valent-pneumococcal-vaccine-candidate/) - PRESS RELEASE Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate The 25 valent pneumococcal conjugate vaccine is designed to broaden protection against life-threatening childhood pneumonia and other serious pneumococcal diseases. REDMOND, Wash.–January 2, 2024–Biotechnology company Inventprise Inc. today announced the completion of vaccination in
- [Inventprise CEO Attends 2nd Global Forum on Childhood Pneumonia](https://inventprise.com/2023/04/27/inventprise-ceo-attends-2nd-global-forum-on-childhood-pneumonia/) - INVENTPRISE IN THE NEWS Inventprise President & CEO Yves Leurquin Attends 2nd Global Forum on Childhood Pneumonia Yves Leurquin shared the vision and mission of Inventprise’s efforts in developing a high valency pneumococcal conjugate vaccine to provide broader coverage during the 2nd Global Forum on Childhood Pneumonia on April 27, 2023 in Madrid, Spain. Watch
- [<em>Every Breath Counts:</em> Pneumococcal Conjugate Vaccine Scorecard 2022](http://inventprise.com/wp-content/uploads/2023/02/INVENT_web_Every-Breath-Counts-PCV-Scorecard.pdf#new_tab)
- [Poster Presentation: Preclinical Results for a 25-Valent Penumococcal Conjugate Vaccine Using A Novel Linker Platform Technology - ISPPD-12 | June, 2022](http://inventprise.com/wp-content/uploads/2023/02/INVENT_ISPPD-2022-PRECLINICAL-RESULTS-FOR-A-25-VALENT-PNEUMOCOCCAL-CONJUGATE-VACCINE-1.pdf#new_tab)
- [PATH: Inventprise’s Expanded-coverage Pneumococcal Vaccine Enters the Clinic](https://cvia.cmail19.com/t/r-e-tjhyidkl-urcikztr-r/#new_tab)
- [<em>Human Vaccines & Immunotherapies:</em> Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production](https://www.tandfonline.com/doi/full/10.1080/21645515.2022.2117949#new_tab)
- [Inventprise Announces Investment of up to $90 Million to Advance its 25 Valent Pneumococcal Conjugate Vaccine Candidate into Proof-of-Concept Clinical Trials](https://inventprise.com/2021/11/10/inventprise-inaugurates-manufacturing-facility-for-high-capacity-supply-of-pneumococcal-conjugate-vaccines-duplicate-7227-2/) - Bill & Melinda Gates Foundation funding will support development of novel vaccine designed to provide broad protection against pediatric pneumococcal disease. Funding builds on over $100 million the foundation has committed to date
- [Precision Vaccinations: Pneumococcal Vaccines 2023](https://www.precisionvaccinations.com/vaccines/pneumococcal-vaccines-2023#new_tab)
- [GeekWire: Seattle-Area Startup Inventprise Gets Backing from Gates Foundation for Pneumonia Shot](https://www.geekwire.com/2021/seattle-area-startup-inventprise-gets-backing-gates-foundation-pneumonia-shot/#new_tab)
- [Gates Notes: A Promising New Vaccine to Protect Children from Their #1 Killer](https://www.gatesnotes.com/Health/Pneumonia-vaccine#new_tab)
- [Biospace: Gates Foundation Pours $90 Million into Promising New Pneumococcal Vaccine](https://www.biospace.com/article/washington-biotech-wins-gates-backing-for-pneumococcal-vaccine-/#new_tab)
- [Inventprise Inaugurates Manufacturing Facility for High-Capacity Supply of Pneumococcal Conjugate Vaccines](https://inventprise.com/2022/05/10/inventprise-inaugurates-manufacturing-facility-for-high-capacity-supply-of-pneumococcal-conjugate-vaccines/) - Highly automated manufacturing facility is expected to provide lifesaving vaccines to low- and middle-income countries, with additional supply to meet global demand.
- [New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation](https://inventprise.com/2022/11/10/new-inventprise-pneumococcal-vaccine-enters-phase-1-2-clinical-evaluation/) - PRESS RELEASE New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation The pneumococcal conjugate vaccine is designed to broaden protection against life-threatening childhood pneumonia and other serious pneumococcal diseases. Redmond, WA (November 10, 2022) – Biotechnology company Inventprise today announced that a Phase 1/2 clinical study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) has
- [Inventprise Receives $30M, Appoints New CEO and Expands Corporate Board](https://inventprise.com/2022/04/07/inventprise-inaugurates-manufacturing-facility-for-high-capacity-supply-of-pneumococcal-conjugate-vaccines-duplicate-7227/) - PRESS RELEASE Inventprise Receives $30M, Appoints New CEO and Expands Corporate Board Funding is the first tranche of up to $90M from Bill & Melinda Gates Foundation to support development of a novel vaccine designed to provide broad protection against pediatric pneumococcal disease Redmond, WA (April 7, 2022) – Inventprise, a biotechnology company specializing in

## Pages

- [Home](https://inventprise.com/) - for a Better World Better Childhoods Better Families Better Lives We are bringing a new generation of vaccines to empower people everywhere to live healthy lives. LEARN MORE We are bringing a new generation of vaccines to empower people everywhere to live healthy lives. LEARN MORE A Better Vaccine: IVT PCV-25 Our lead candidate, Pneumococcal
- [About Us](https://inventprise.com/about-us/) - About Inventprise Inventprise is leveraging its innovative platform technology to develop vaccines against infectious diseases with an initial focus on invasive pneumococcal disease. About Inventprise Inventprise platform technologies are designed to enable high valent vaccines to induce broad, robust, and durable protection against pathogenic strains of infectious diseases.In addition to its lead candidate, the 25-valent
- [Contact](https://inventprise.com/contact/) - Contact Us Business Enquiriesbusiness@inventprise.comGeneral Contactinfo@inventprise.com Inventprise15323 Redmond – Woodinville Rd NE,Woodinville, WA 98072+1 206-258-2660 Inventprise U.S. Locations Development &Phase 1 Product Manufacturing 18133 NE 68th St, D150,Redmond, WA 98052 (F1) Small Scale cGMP Manufacturing 18465 NE 68th St, #101Redmond, WA 98052 (F3) Large-Scale Manufacturing 15323 Redmond – Woodinville Rd NE,Woodinville, WA 98072 (F4) Inventprise European
- [Open Positions](https://inventprise.com/careers/open-positions/) - Join the Inventprise Team Our People-First Philosophy Employee Benefits Our Locations About Inventprise
- [Benefits](https://inventprise.com/careers/benefits/) - Benefits At Inventprise, we believe people are our most valuable asset. We value and respect our people for the skills and experiences that they bring, and provide them with growth opportunities, competitive benefits, and a diverse and inclusive culture where everyone contributes to our success. What we offer 401(k) Plan Inventprise offers both pre-tax 401(k)
- [News & Publications](https://inventprise.com/news-publications/) - News & Publications Inventprise Press Releases Inventprise Announces Positive Interim Results from the Phase 1/2 clinical study for Hexavalent Group B Streptococcal Vaccine Candidate (IVT GBS-06) • February 23, 2026 Inventprise Announces Breakthrough in COVID-19 Conjugate Vaccine Study Published in Vaccine Journal • June 24, 2025 Inventprise Selects Quantoom Biosciences’ Ntensify® Production Technology to Advance
- [Manufacturing](https://inventprise.com/manufacturing/) - Manufacturing With more than 100,000 square feet of manufacturing facilities, our comprehensive suite of capabilities supports a diverse portfolio of products. Tour Our Facilities Three Inventprise facilities in the Redmond, Washington, area offer capabilities from product development to analytical to manufacturing – enabling us to support the broad range of products in our pipeline.Our dedicated
- [Technology](https://inventprise.com/technology/) - Technology Inventprise’s proprietary scalable Conjugation Technology Platform is based on the bi-functional PEG linker, Hydrazide-PEG-Hydrazide, designed to create highly immunogenic, and broad-spectrum conjugate vaccines The linker-based conjugates elicit significantly higher IgG and functional OPA titers (immunogenicity) compared to the same PS-conjugate without the linker.Increased availability of antigenic PS epitopes of the carrier protein reduces the
- [Pipeline](https://inventprise.com/pipeline/) - Pipeline Inventprise platform technologies support a robust pipeline of novel vaccines with the potential to unlock large market opportunities with significant unmet medical needs Discovery Preclinical Phase 1 Phase 2 Phase 3 Registration IVT PCV-25* – AdultLead Candidate 25-valent Pneumococcal Conjugate IVT PCV-25* – InfantLead Candidate 25-valent Pneumococcal Conjugate IVT GBS-06*Hexavalent Group B Streptococcal Vaccine
- [Careers](https://inventprise.com/careers/) - Careers at Inventprise Our People-First Philosophy Employee Benefits Our Locations About Inventprise Join Our Team At Inventprise, developing innovative and widely available vaccines is in our DNA. We believe that a healthy and inclusive workplace culture inspires our people to do their best work, and we’re proud to have some of the world’s most qualified
- [Careers - Header Test](https://inventprise.com/header-test/) - Careers at Inventprise Careers at Inventprise 1 Careers at Inventprise 2 Careers at Inventprise 3 Careers at Inventprise 4 Careers at Inventprise 5 Our People-First Philosophy Employee Benefits Our Locations About Inventprise Join Our Team At Inventprise, developing innovative and widely available vaccines is in our DNA. We believe that a healthy and inclusive workplace
- [Pipeline-REV-11](https://inventprise.com/pipeline-rev-11/) - Pipeline Inventprise platform technologies support a robust pipeline of novel vaccines with the potential to unlock large market opportunities with significant unmet medical needs Discovery Preclinical Phase 1 Phase 2 Phase 3 Registration IVT PCV-25* – AdultLead Candidate 25-valent Pneumococcal Conjugate IVT PCV-25* – InfantLead Candidate 25-valent Pneumococcal Conjugate IVT GBS-06*Hexavalent Group B Streptococcal Vaccine
- [Contract Services](https://inventprise.com/contract-services/) - Contract Services Inventprise offers our diverse services in biologics from process-to-end user. We have wide ranging experience in process development, optimization, servicing analytical needs and manufacturing from early clinical trials through commercialization. We can assist in advancing your program by leveraging our subject matter experts in protein purification, cell culture, conjugation chemistry, and automated commercial
- [Privacy Policy](https://inventprise.com/privacy-policy/) - Inventprise Privacy Policy for Website Last Updated February 6, 2023 Terms of Use The following Terms of Use govern and apply to your use of this, and any other website maintained by Inventprise, Inc., including its subsidiaries or affiliates (collectively referred to as “Inventprise”). Access and/or use of this Inventprise website are subject to the
- [Pipeline - OLD CONTENT](https://inventprise.com/pipeline-old-content/) - Pipeline Inventprise platform technologies support a robust pipeline of novel vaccines with the potential to unlock large market opportunities with significant unmet medical needs Phase 1 Phase 2 Phase 3 Registration IVT PCV-25Lead Candidate 25-valent Pneumococcal Conjugate Vaccine IVT GBS-06Hexavalent Group B Streptococcus Vaccine IVT Shigella-04Quadrivalent Shigella Vaccine Learn More About Our Pipeline Programs Multivalent
- [Members](https://inventprise.com/member/)
- [Inventprise In the News Archive](https://inventprise.com/inventprise-in-the-news-archive/) - Inventprise Press Release Archive Path.com: A Deadly Disease for Infants Has No Vaccine—We’re Changing That January 28, 2025 Inventprise CEO Attends 2nd Global Forum on Childhood Pneumonia April 27, 2023 Every Breath Counts: Pneumococcal Conjugate Vaccine Scorecard 2022 February 6, 2023 PATH: Inventprise’s Expanded-coverage Pneumococcal Vaccine Enters the Clinic February 3, 2023 Precision Vaccinations: Pneumococcal
- [Inventprise Press Release Archive](https://inventprise.com/inventprise-press-release-archive/) - Inventprise Press Release Archive Inventprise Announces Positive Interim Results from the Phase 1/2 clinical study for Hexavalent Group B Streptococcal Vaccine Candidate (IVT GBS-06) February 23, 2026 Inventprise Announces Breakthrough in COVID-19 Conjugate Vaccine Study Published in Vaccine Journal June 24, 2025 Inventprise Selects Quantoom Biosciences’ Ntensify® Production Technology to Advance mRNA Vaccine Development May
- [Pipeline-LONGTERM](https://inventprise.com/pipeline-longterm/) - Pipeline Vaccine ProgramsCollaborations
- [Portfolios](https://inventprise.com/portfolio/)
- [Testimonials](https://inventprise.com/testimonials/) - Satisfied Clients Say About Us We love to design & develop awesome websites and Join over 50,000+ users who love us. Our customer's reviews on Theme Forest.
- [Services](https://inventprise.com/services/)
- [FAQ](https://inventprise.com/faq/) - Customer Management Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Donec odio. Quisque volutpat mattis eros. Nullam malesuada erat ut turpis. Suspendisse urna nibh, viverra non, semper suscipit, posuere a, pede. Donec nec justo eget felis facilisis fermentum. Aliquam porttitor mauris sit amet orci. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Donec odio. Quisque

## My Templates

- [Default Kit](https://inventprise.com/?elementor_library=default-kit-2)
- [Default Kit](https://inventprise.com/?elementor_library=default-kit)

## UDesign Templates

- [Header](https://inventprise.com/udesign_template/header/) - Home About Us Executive Leadership Management Team Board of Directors Scientific Advisory Board Pipeline Technology Conjugation Linker Technology Manufacturing Facilities Contract Services News & Publications Press Releases Inventprise In the News Publications Careers Our People-First Philosophy Join the Inventprise Team Benefits Contact
- [Footer](https://inventprise.com/udesign_template/footer/) - About Us Pipeline Technology Manufacturing News Careers Contact Contact Inventprise Follow Us ©2026 Inventprise. All Rights Reserved. Privacy Policy Whistleblower Policy
- [About Us Page Header](https://inventprise.com/udesign_template/about-us-page-header/)
- [Custom Shop](https://inventprise.com/udesign_template/custom-shop/)
- [Testimonial Page Header](https://inventprise.com/udesign_template/testimonial-page-header/) - Testimonials What Customers Says
- [Services Page Header](https://inventprise.com/udesign_template/services-page-header/) - Our Services You Dream it, We Make It True
- [Faq Page Header](https://inventprise.com/udesign_template/faq-page-header/) - Knowledgebase Frequently Asked Questions
- [Contact Us Page Header](https://inventprise.com/udesign_template/contact-us-page-header/) - Get in Touch Contact Us
- [Blog Page Header Block](https://inventprise.com/udesign_template/blog-page-header-block/) - Recent News
- [Shop Banner Block](https://inventprise.com/udesign_template/shop-banner-block/) - Get up to 20%Off Hot Sales Shop Now

## Members

- [Pradhip Ghate, MS, MBA](https://inventprise.com/member/subhash-kapre/) - Pradip Ghate has over three decades of international experience working in developing and developed countries in Project and Operations management for Aseptic Sterile operations of biological and pharmaceutical products. He has direct experience managing multiple disciplines from Aseptic manufacturing, Quality Assurance, Quality Engineering and Systems Validation, Formulation, Fill, Finish & Packaging. His tenure at Serum
- [Mary Ann](https://inventprise.com/member/mary-ann/) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Venenatis tellus in metus vulputate eu. Ultrices eros in cursus turpis massa tincidunt. Ante in nibh mauris cursus mattis. Cras ornare arcu dui vivamus arcu felis bibendum ut tristique. Ac tincidunt vitae semper quis lectus. Etiam
- [Janice Doe](https://inventprise.com/member/janice-doe/) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Venenatis tellus in metus vulputate eu. Ultrices eros in cursus turpis massa tincidunt. Ante in nibh mauris cursus mattis. Cras ornare arcu dui vivamus arcu felis bibendum ut tristique. Ac tincidunt vitae semper quis lectus. Etiam
- [Alice Doe](https://inventprise.com/member/alice-doe/) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Venenatis tellus in metus vulputate eu. Ultrices eros in cursus turpis massa tincidunt. Ante in nibh mauris cursus mattis. Cras ornare arcu dui vivamus arcu felis bibendum ut tristique. Ac tincidunt vitae semper quis lectus. Etiam
- [Rick Edward](https://inventprise.com/member/rick-edward/) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Venenatis tellus in metus vulputate eu. Ultrices eros in cursus turpis massa tincidunt. Ante in nibh mauris cursus mattis. Cras ornare arcu dui vivamus arcu felis bibendum ut tristique. Ac tincidunt vitae semper quis lectus. Etiam
- [Robin Doe](https://inventprise.com/member/robin-doe/) - Lorem Ipsum. Proin gravida nibh vel velit auctor aliquet. Aenean sollicitudin, lorem quis bibendum auctor nisi elit consequat.
- [Viktoriia Demianenko](https://inventprise.com/member/viktoriia-demianenko/) - Lorem Ipsum. Proin gravida nibh vel velit auctor aliquet. Aenean sollicitudin, lorem quis bibendum auctor nisi elit consequat.
- [Tomasz Treflerzan](https://inventprise.com/member/tomasz-treflerzan/) - Lorem Ipsum. Proin gravida nibh vel velit auctor aliquet. Aenean sollicitudin, lorem quis bibendum auctor nisi elit consequat.

## Categories

- [Press Release](https://inventprise.com/category/press-release/)
- [Inventprise In the News](https://inventprise.com/category/in-the-news/)
- [Publications](https://inventprise.com/category/publications/)

## Member categories

- [CEO / Founder](https://inventprise.com/member_cat/ceo-founder/)
- [Co-Founder](https://inventprise.com/member_cat/co-founder/)
- [Designer](https://inventprise.com/member_cat/designer/)
- [Sales](https://inventprise.com/member_cat/sales/)
- [Support](https://inventprise.com/member_cat/support/)
- [Executive Leadership](https://inventprise.com/member_cat/executive-leadership/)